The Translation Cycle: round and round in cycles is the only way forward for regenerative medicine
Bibliography
- 1 Mason C, Manzotti E: Regen: the industry responsible for cell-based therapies. Regen. Med.4(6),783–785 (2009).
- 2 No authors listed. To thwart disease, apply now. Nature453(7197),823 (2008).
- 3 Dietz AB, Padley DJ, Gastineau DA: Infrastructure development for human cell therapy translation. Clin. Pharmacol. Ther.82(3),320–324 (2007).
- 4 Ledford H: Translational research: the full cycle. Nature453(7197),843–845 (2008).
- 5 Spack E: Minding the drug development gap. The Scientist19(21),36–37 (2005).
- 6 Klausner A: Mind the (biomedical funding) gap. Nat. Biotechnol.23(10),1217–1218 (2005).
- 7 Sung NS, Crowley WF Jr, Genel M et al.: Central challenges facing the national clinical research enterprise. JAMA289(10),1278–1287 (2003).
- 8 Cooksey D: A review of UK health research funding. HMSO, London, UK (2006).
- 9 Woolf SH: The meaning of translational research and why it matters. JAMA299(2),211–213 (2008).
- 10 Hunziker E, Spector M, Libera J et al.: Translation from research to applications. Tissue Eng.12(12),3341–3364 (2006).
- 11 Kerner JF: Knowledge translation versus knowledge integration: a “funder’s” perspective. J. Contin. Educ. Health Prof.26(1),72–80 (2006).
- 12 Butler D: Translational research: crossing the valley of death. Nature453(7197),840–842 (2008).
- 101 National Institute for Health and Clinical Excellence (NICE). Our Guidance. www.nice.org.uk/guidance/index.jsp
- 102 Technology Strategy Board press release. Regenerative Medicine research and development to receive £4.5 million funding injection. 15th January 2010. www.innovateuk.org/_assets/pdf/press-releases/press%20release%20-%20regenmed%20results%2015jan10%20final.pdf